前瞻性试验中新型生物标志物的整合：来自CHOICE-01的生物学见解

IF 40.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Signal Transduction and Targeted Therapy Pub Date : 2024-12-05 DOI:10.1038/s41392-024-02078-7

Edward Christopher Dee, Puneeth Iyengar

{"title":"前瞻性试验中新型生物标志物的整合：来自CHOICE-01的生物学见解","authors":"Edward Christopher Dee, Puneeth Iyengar","doi":"10.1038/s41392-024-02078-7","DOIUrl":null,"url":null,"abstract":"The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in Signal Transduction and Targeted Therapy,1 recapitulated findings from an earlier publication of the trial.2 The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable EGFR or ALK mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"16 1","pages":""},"PeriodicalIF":40.8000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Integration of novel biomarkers in prospective trials: biological insights from CHOICE-01\",\"authors\":\"Edward Christopher Dee, Puneeth Iyengar\",\"doi\":\"10.1038/s41392-024-02078-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in Signal Transduction and Targeted Therapy,1 recapitulated findings from an earlier publication of the trial.2 The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable EGFR or ALK mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.\",\"PeriodicalId\":21766,\"journal\":{\"name\":\"Signal Transduction and Targeted Therapy\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":40.8000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Signal Transduction and Targeted Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41392-024-02078-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signal Transduction and Targeted Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41392-024-02078-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近发表在《信号转导和靶向治疗》（Signal Transduction and Targeted Therapy）杂志上的CHOICE-01研究报告了总生存期（OS），总结了该试验早期发表的研究结果选择-01研究人员前瞻性地将没有靶向EGFR或ALK突变的局部晚期（IIIB或IIIC）或转移性非小细胞肺癌（NSCLC）患者随机分配到有或没有托利帕单抗（一种人源化PD-1定向IgG4抗体）的化疗中，并证明托利帕单抗可改善OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Integration of novel biomarkers in prospective trials: biological insights from CHOICE-01

查看原文本刊更多论文

Integration of novel biomarkers in prospective trials: biological insights from CHOICE-01

The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in Signal Transduction and Targeted Therapy,¹ recapitulated findings from an earlier publication of the trial.² The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable EGFR or ALK mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Signal Transduction and Targeted Therapy Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

44.50

自引率

1.50%

发文量

384

审稿时长

5 weeks

期刊介绍： Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy. Scope: The journal covers research on major human diseases, including, but not limited to: Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.